Cargando…

EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer

BACKGROUND: Cisplatin-based chemotherapy is recommended as the primary treatment for advanced bladder cancer (BC) with unresectable or metastatic disease. However, the benefits are limited due to the acquisition of drug resistance. The mechanisms of resistance remain unclear. Although there are some...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okamura, Shunsuke, Yoshino, Hirofumi, Kuroshima, Kazuki, Tsuruda, Masafumi, Osako, Yoichi, Sakaguchi, Takashi, Yonemori, Masaya, Yamada, Yasutoshi, Tatarano, Shuichi, Nakagawa, Masayuki, Enokida, Hideki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798329/ https://www.ncbi.nlm.nih.gov/pubmed/33430801 http://dx.doi.org/10.1186/s12885-020-07717-0

Ejemplares similares

Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation
por: Yoshino, Hirofumi, et al.
Publicado: (2020)

Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma
por: Yoshino, Hirofumi, et al.
Publicado: (2020)

Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant
por: Tsuruda, Masafumi, et al.
Publicado: (2020)

Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma
por: Kuroshima, Kazuki, et al.
Publicado: (2020)

microRNA‐99a‐5p induces cellular senescence in gemcitabine‐resistant bladder cancer by targeting SMARCD1
por: Tamai, Motoki, et al.
Publicado: (2022)

Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor
por: Yoshino, Hirofumi, et al.
Publicado: (2023)

Significance of preoperative screening of deep vein thrombosis and its indications for patients undergoing urological surgery
por: Tatarano, Shuichi, et al.
Publicado: (2021)

Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer
por: Sakaguchi, Takashi, et al.
Publicado: (2018)

Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer
por: Sakaguchi, Takashi, et al.
Publicado: (2017)

microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma
por: Yoshino, Hirofumi, et al.
Publicado: (2017)

Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma
por: Sakaguchi, Takashi, et al.
Publicado: (2018)

Kidney transplantation with concomitant simple nephrectomy by thoracoabdominal approach for patients with huge autosomal dominant polycystic kidney disease (ADPKD): A case report
por: Yamada, Yasutoshi, et al.
Publicado: (2019)

Laparoscopic Surgery for Pheochromocytoma in Hemodialysis Patients
por: Tatarano, Shuichi, et al.
Publicado: (2022)

Low dose tacrolimus exposure and early steroid withdrawal with strict body weight control can improve post kidney transplant glucose tolerance in Japanese patients
por: Mitsuke, Akihiko, et al.
Publicado: (2023)

Dual tumor‐suppressors miR‐139‐5p and miR‐139‐3p targeting matrix metalloprotease 11 in bladder cancer
por: Yonemori, Masaya, et al.
Publicado: (2016)

Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p): inhibition of bladder cancer cell aggressiveness
por: Matsushita, Ryosuke, et al.
Publicado: (2016)

Long-term desensitization for ABO-incompatible living related kidney transplantation recipients with high refractory and rebound anti-blood type antibody: case report
por: Nishimura, Hiroaki, et al.
Publicado: (2018)

Novel oncogenic function of mesoderm development candidate 1 and its regulation by MiR-574-3p in bladder cancer cell lines
por: TATARANO, SHUICHI, et al.
Publicado: (2011)

Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma
por: Hidaka, Hideo, et al.
Publicado: (2012)

The role of microRNAs in bladder cancer
por: Enokida, Hideki, et al.
Publicado: (2016)

Tumor suppressive microRNA-138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma
por: YAMASAKI, TAKESHI, et al.
Publicado: (2012)

Distinct Mitochondrial Pathologies Caused by Mutations of the Proximal Tubular Enzymes EHHADH and GATM
por: Forst, Anna-Lena, et al.
Publicado: (2021)

Potential therapeutic target secretogranin II might cooperate with hypoxia‐inducible factor 1α in sunitinib‐resistant renal cell carcinoma
por: Fukumoto, Wataru, et al.
Publicado: (2023)

Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer
por: CHIYOMARU, TAKESHI, et al.
Publicado: (2014)

The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer
por: Yoshino, H, et al.
Publicado: (2011)

Increased EHHADH Expression Predicting Poor Survival of Osteosarcoma by Integrating Weighted Gene Coexpression Network Analysis and Experimental Validation
por: Cui, Juncheng, et al.
Publicado: (2021)

Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer
por: Miyamoto, K, et al.
Publicado: (2016)

Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma
por: YAMAMOTO, NORIKO, et al.
Publicado: (2013)

The potential contribution of miRNA-200-3p to the fatty acid metabolism by regulating AjEHHADH during aestivation in sea cucumber
por: Chen, Muyan, et al.
Publicado: (2018)

Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma
por: Kinoshita, Takashi, et al.
Publicado: (2012)

The MicroRNA Expression Signature of Bladder Cancer by Deep Sequencing: The Functional Significance of the miR-195/497 Cluster
por: Itesako, Toshihiko, et al.
Publicado: (2014)

Tumor-suppressive microRNA-29a inhibits cancer cell migration and invasion via targeting HSP47 in cervical squamous cell carcinoma
por: YAMAMOTO, NORIKO, et al.
Publicado: (2013)

LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling
por: Matsuda, R, et al.
Publicado: (2011)

miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma
por: Nohata, Nijiro, et al.
Publicado: (2011)

Genistein Inhibits Prostate Cancer Cell Growth by Targeting miR-34a and Oncogenic HOTAIR
por: Chiyomaru, Takeshi, et al.
Publicado: (2013)

Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial
por: Terazawa, Tetsuji, et al.
Publicado: (2014)

miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer
por: Chiyomaru, T, et al.
Publicado: (2010)

Active Efflux System for Cisplatin in Cisplatin‐resistant Human KB Cells
por: Fujii, Ryu‐ichi, et al.
Publicado: (1994)

Tumour-suppressive microRNA-144-5p directly targets CCNE1/2 as potential prognostic markers in bladder cancer
por: Matsushita, R, et al.
Publicado: (2015)

Effects of 5‐HT(₃) receptor antagonists on cisplatin‐induced kidney injury
por: Goda, Mitsuhiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fdqudhjmb485c7s3jscd6tv2h1